Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus TAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus TAVIST.
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs TAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, reducing allergic symptoms; it also has anticholinergic, antiemetic, and sedative effects. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects by central mechanisms.
Antihistamine; selective inverse agonist at histamine H1 receptors, blocking histamine-mediated allergic and inflammatory responses.
Adults: 5 mL (containing promethazine 6.25 mg and codeine 10 mg) orally every 4-6 hours as needed; maximum 30 mL per day.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Promethazine: 10-19 hours (range 5-30h); Codeine: 2.5-4 hours (rapidly metabolized); Clinical context: sustained antitussive effect from codeine despite short half-life. Half-life of promethazine extends with hepatic impairment.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in renal/hepatic impairment.
Renal: Codeine and metabolites ~90% (free and conjugated), Promethazine and metabolites primarily renal; minor biliary/fecal (<5% for codeine, ~6% for promethazine).
Renal excretion of metabolites (approx. 60%) and unchanged drug (<5%); biliary/fecal elimination accounts for about 40%.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine